Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CPS1 | P31327 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28719848 | 0.82 | SETD7 (0.47) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL3392879 | 0.82 | SETD7 (0.47) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL28719794 | 0.82 | SETD7 (0.47) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL3395559 | 0.82 | SETD7 (0.47) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL13130609 | 0.82 | TSHR (0.43) | PDK1PDK2PDK3PDK4TSHR | |
| SCHEMBL10196629 | 0.81 | TSHR (0.34) | PDK1PDK2PDK3PDK4LMNA | |
| SCHEMBL6906792 | 0.77 | PDK1 (0.48) | PDK1PDK2PDK3PDK4LMNA | |
| SCHEMBL27115233 | 0.76 | PDK2 (0.37) | PDK2 | |
| SCHEMBL27326098 | 0.76 | PDK2 (0.37) | PDK2 | |
| SCHEMBL27326097 | 0.76 | PDK2 (0.37) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249411-A1 | Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines | WU WENXUE | 2010-09-30 | — | — | US | disclosed |
| US-7745626-B2 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | SCHERING CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2141143-A2 | Stereoselective alkylation of chiral 2-methyl-4 protected piperazines | SCHERING CORPORATION (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2141153-A2 | Stereoselective alkylation of chiral 2-methyl-4 protected piperazines | SCHERING CORPORATION (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-1490346-B1 | STEREOSELECTIVE ALKYLATION OF CHIRAL 2-METHYL-4-PROTECTED PIPERAZINES | SCHERING CORP (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20050171120-A1 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | WU WENXUE (US) | 2005-08-04 | — | — | US | disclosed |
| US-6872826-B2 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | SCHERING CORPORATION (US) | 2005-03-29 | — | — | US | disclosed |
| US-20030208074-A1 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | SCHERING CORPORATION | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171120-A1 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | AZI2, ALKBH5, DNMT1 | PDK1 4138/4885PDK2 2863/4885PDK3 3460/4885 |
| US-20030208074-A1 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | AZI2, DNMT1, ALKBH5 | PDK1 4010/4885PDK2 2784/4885PDK3 3357/4885 |
| US-20100249411-A1 | Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines | ALKBH5, AZI2, PNMT | PDK1 4262/4885PDK2 3049/4885PDK3 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.